{"title":"SOX superior to CAPOX in resectable G/GEJ cancer","authors":"Peter Sidaway","doi":"10.1038/s41571-025-01010-4","DOIUrl":null,"url":null,"abstract":"<p>Most patients undergoing surgery for locally advanced gastric or gastroesophageal junction (G/GEJ) cancer will require chemotherapy; however, the optimum approach, including the most effective regimen and whether perioperative chemotherapy is more effective than an adjuvant-only approach, remains uncertain. Now, 5-year follow-up data from the phase III RESOLVE trial provide evidence supporting the use of adjuvant S-1 plus oxaliplatin (SOX) in these patients.</p><p>A total of 1,094 patients with histologically confirmed cT4a N+ M0 or cT4b any N-stage M0 G/GEJ adenocarcinoma were randomly assigned (1:1:1) to receive either adjuvant SOX, adjuvant capecitabine plus oxaliplatin (CAPOX), or perioperative SOX. This study was conducted at 27 hospitals across China. Disease-free survival (DFS) at 3 years was the primary end point and was described in a previous report.</p>","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":"53 1","pages":""},"PeriodicalIF":81.1000,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature Reviews Clinical Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41571-025-01010-4","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Most patients undergoing surgery for locally advanced gastric or gastroesophageal junction (G/GEJ) cancer will require chemotherapy; however, the optimum approach, including the most effective regimen and whether perioperative chemotherapy is more effective than an adjuvant-only approach, remains uncertain. Now, 5-year follow-up data from the phase III RESOLVE trial provide evidence supporting the use of adjuvant S-1 plus oxaliplatin (SOX) in these patients.
A total of 1,094 patients with histologically confirmed cT4a N+ M0 or cT4b any N-stage M0 G/GEJ adenocarcinoma were randomly assigned (1:1:1) to receive either adjuvant SOX, adjuvant capecitabine plus oxaliplatin (CAPOX), or perioperative SOX. This study was conducted at 27 hospitals across China. Disease-free survival (DFS) at 3 years was the primary end point and was described in a previous report.
期刊介绍：
Nature Reviews publishes clinical content authored by internationally renowned clinical academics and researchers, catering to readers in the medical sciences at postgraduate levels and beyond. Although targeted at practicing doctors, researchers, and academics within specific specialties, the aim is to ensure accessibility for readers across various medical disciplines. The journal features in-depth Reviews offering authoritative and current information, contextualizing topics within the history and development of a field. Perspectives, News & Views articles, and the Research Highlights section provide topical discussions, opinions, and filtered primary research from diverse medical journals.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
